Glitaray M 2mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these two agents effectively controls hyperglycemia in patients inadequately managed by diet and exercise alone. Glitaray M is typically prescribed when monotherapy with either agent is insufficient to achieve glycemic targets. It is essential to initiate therapy with caution, monitoring blood glucose levels regularly to minimize the risk of hypoglycemia, particularly due to Glimepiride. Metformin’s use is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which tend to subside with continued use. Patient adherence to prescribed dosage and lifestyle modifications is critical for optimal therapeutic outcomes. Regular monitoring of renal function and periodic assessment of glycemic control are recommended during treatment with Glitaray M 2mg/500mg Tablet.